InHouse Medical LLC

02/15/2026

New Study: Who’s Starting the Wegovy® Pill?

Big update in the weight management space.

A recent nationwide analysis (Truveta, Feb 2026) looked at early users of the new oral Wegovy® (semaglutide) pill, the first GLP-1 tablet approved for chronic weight management.

Here’s what stands out:

• 36% of patients were completely new to GLP-1 medications**
• 21.1% previously used injectable Wegovy®
• 15.8% switched from Zepbound®
• 73% of early users are women
• Majority are age 45+
• GLP-1 prescriptions now make up **over 7% of all prescriptions nationwide**

What does this mean?

The pill isn’t just replacing injections, it’s bringing new patients into treatment who may have avoided injectables altogether.

For many people, the barrier was never the science.
It was the needle.

Now there’s another option.

At InHouse Medical, we focus on structured, medically supervised weight management, whether that includes GLP-1 injections, oral therapy, or a customized protocol based on your labs and metabolic profile.

If you’ve been curious about GLP-1 medications but hesitant about injections, this may be the moment to revisit the conversation.

📍 Waterbury, CT
💻 Telehealth available
🔬 Comprehensive evaluation required before starting treatment

Weight loss isn’t about trends.
It’s about strategy, safety, and long-term optimization.

Message us to schedule a consultation at (203)518-5232

Respaut, R. (2026, February 11). More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds. Reuters.

Call now to connect with business.

01/25/2026

The hidden factor that may explain why semaglutide works better for some people-

We talk a lot about medications like semaglutide and empagliflozin helping with blood sugar and weight, but another important piece of the puzzle often doesn’t get attention: the gut microbiome.

Recent research shows that starting medications such as semaglutide or empagliflozin can actually change the makeup of the gut microbiome in people with type 2 diabetes. Interestingly, while the overall diversity of gut bacteria did not change, the specific types of bacteria did shift after treatment began. Even more fascinating, a person’s gut microbiome before starting treatment helped predict how much their A1C would improve on these medications.

In other words, it’s not just the medication acting on the body. The gut and the medication are interacting, and that relationship may influence how well the treatment works. This adds to the growing evidence that our gut health plays a meaningful role in how we respond to modern diabetes and weight loss therapies.

As we learn more, this kind of research may help explain why some people respond incredibly well to medications like semaglutide, while others see more modest results. Personalized medicine may be closer than we think.

Source: Effects of Semaglutide and Empagliflozin on the Gut Microbiome in Type 2 Diabetes Patients, analyzed using 16S rRNA gene sequencing.

Treat gut health as part of the treatment plan, not an afterthought.

Smaller meals; stop eating at the first sign of fullness.

Protein first, then vegetables, then starch.

Add fiber gradually (do not jump from low fiber to high fiber in a week).

1. If constipation: increase fluids, magnesium citrate, or polyethylene glycol as appropriate, plus fiber titration. Treat early rather than waiting.

2. Smaller meals; stop eating at the first sign of fullness.

3. Protein first, then vegetables, then starch.

4. Add fiber gradually (do not jump from low fiber to high fiber in a week).

5. You do not need stool microbiome testing as a routine “predictor” of semaglutide outcomes. This is not standard-of-care, interpretation is inconsistent, and it can create more confusion than value. However, if your sturggling, getting GI map may be helpful.

www.inhousemedicine.com

Call now to connect with business.

01/19/2026

A lot of people ask me the same question: “Once I lose the weight on a GLP-1, can I come off of it?”

Totally fair question. Most people don’t want to be on a medication forever, and I get that.

But a new study that just came out this week in The BMJ looked at what happens after people stop medications like semaglutide or tirzepatide, and the results were pretty eye-opening.

They reviewed over 9,000 people across 37 studies, and the pattern was consistent. After stopping, most people gradually regained the weight, and a lot of the health improvements started to fade too. On average, people were back near their starting weight within about 1.5 to 2 years. Things like blood sugar, blood pressure, cholesterol, and triglycerides also trended back toward baseline within a similar timeframe.

Here’s the part I want people to understand without feeling discouraged. This does not mean these medications don’t work. They work really well. The bigger point is that obesity is a chronic condition for many people, and chronic conditions usually require a long-term plan, not just a short-term push.

In other words, GLP-1s can be an excellent tool, but they are not a “one and done” solution for most patients.

This is why I spend so much time upfront talking about maintenance. Some people do best staying on a medication long-term. Some transition to a lower dose. Some need a different strategy entirely. The key is not stopping suddenly without a plan and then blaming yourself when appetite comes roaring back and the weight starts creeping up.

If you are on a GLP-1 now, or thinking about starting, my advice is simple. Don’t just ask, “How fast can I lose weight?” Ask, “What is my plan to keep it off?”

If you want help building that plan, that’s what we do at InHouse Medical.

www.inhousemedicine.com
(203)518-5232

01/11/2026

GLP-1 meds (like semaglutide and tirzepatide) have been a game-changer for a lot of people, but they’re not magic for everyone.

A small group of patients just don’t see the kind of weight loss we’d expect early on. In one report, “nonresponse” was basically defined as not losing at least 5% of body weight after about 3 months on a GLP-1. And depending on the medication, that can be somewhere around 10–17% of patients.

If that’s you, here’s the important part: it’s not a character flaw, and it’s not “you did something wrong.”

There are a bunch of reasons this can happen, including:

biology/genetics (some bodies just respond differently),
other medical issues (thyroid problems, PCOS, Cushing syndrome, diabetes, etc.), medications that can cause weight gain (steroids, some antidepressants, some antipsychotics), not being able to get to an effective dose (side effects, slow titration, staying too low too long) stress and sleep (yes, they matter more than people realize), age-related changes, also, some people are “late responders,” meaning it takes longer than 12 weeks to see the first real drop.

Bottom line: if you’re not seeing results, don’t assume you failed. It usually just means we need to zoom out, look at the full picture, and adjust the plan (dose, labs, meds, lifestyle barriers, or even a different treatment option).

When GLP-1s Fall Short: Some Patients Don’t Find Success. Medscape Medical News, January 6, 2026. WebMD, LLC.

Inhousemedicine.com

Call now to connect with business.

01/06/2026

101.8K likes, 2644 comments. “Menopause isn't just ovaries—it's brain health. Estrogen loss triggers disease, aging. It's time healthcare catches up to science.”

12/14/2025

Interesting medical insight I came across this week:
There’s new research suggesting that semaglutide, a medication commonly used for type 2 diabetes and weight management, may be linked to a much lower risk of developing adult-onset epilepsy in people with diabetes. The reduction was around 50 percent compared to other diabetes medications.

What stood out to me is that this effect didn’t seem to be explained by better blood sugar control or weight loss alone. That points toward a possible direct benefit on brain health, not just metabolism.

We’ve already seen data showing GLP-1 medications may have protective effects in conditions like stroke and dementia. This adds another layer to the conversation and suggests there may be something unique going on in the brain when these medications are used.

One physician involved in the discussion mentioned that for patients with type 2 diabetes who also have a higher risk of seizures, semaglutide could be worth considering with overall brain health in mind, not just cardiovascular or glucose outcomes.

This is still early research and not medical advice, but it’s a good reminder that these medications are more complex than the weight loss headlines make them seem. The more we learn, the clearer it becomes that metabolic health and brain health are deeply connected.

Always interesting to watch where science goes next.


Semaglutide Tied to 50% Lower Risk for Epilepsy in Diabetes - Medscape - December 10, 2025

12/07/2025

New Research Alert: Certain Medications May Increase the Risk of PCOS

Polycystic O***y Syndrome (PCOS) affects millions of women worldwide. Still, a new large-scale study just uncovered something important: some commonly used medications may be linked to an increased risk of developing PCOS-like symptoms.

Using over 10 years of data from the FDA Adverse Event Reporting System (FAERS), researchers reviewed more than 1,500 cases. They identified 18 medications that showed a significant association with PCOS-related side effects.

Here’s what the study found:

• Medications most often linked to PCOS risk included certain antipsychotics, anticonvulsants, steroid-based inhalers, bronchodilators, hormonal agents, and even some antiviral drugs.
• The strongest signals were seen with Mecasermin, Ciclesonide, Valproic Acid, and Olanzapine.
• PCOS symptoms tended to appear either within the first 30 days of starting a medication or after long-term use (over 1 year).
• Women ages 20–39 reported the highest number of medication-related PCOS cases.

Why does this matter?
PCOS is not just about irregular periods — it’s linked to infertility, metabolic issues, diabetes, heart disease, and chronic inflammation. Understanding which medications may affect hormonal balance helps healthcare providers choose safer treatments and monitor patients more closely.

What this study doesn’t claim:
It does not say these drugs cause PCOS.
It does not recommend stopping any prescribed medication.
It does highlight the need for awareness, monitoring, and more research.

The Bottom Line:
This is the first large study to systematically analyze medications linked to PCOS symptoms across millions of FDA reports. It’s a reminder that women's health deserves deeper research — especially when it comes to how medications may influence hormones and long-term health.

If you or someone you know is taking medications for asthma, seizures, mental health, or chronic illness and has symptoms like irregular cycles, acne, weight changes, or hair growth, talk to your healthcare provider about whether medication could be playing a role.

Your health story matters — and studies like this help all of us make more informed decisions.
Data summarized from a large-scale analysis of the FDA Adverse Event Reporting System (FAERS), 2014–2024, examining potential medication associations with polycystic o***y syndrome (PCOS).

www.InHouseMedicine.com

We accept insurance. Obtain your Wegovy and Zepbound if you qualify from the pharmacy.

11/16/2025

New Research: Tirzepatide Shows Powerful Weight-Loss Results for Women with PCOS

At InHouse Medical, we stay on top of the latest science so you can feel confident in your care. The newest data on Tirzepatide for women with PCOS is big news.

A real-world analysis of over 4,200 women with PCOS, overweight, or obesity found significant weight loss with Tirzepatide treatment:

-Average weight loss of 18.8% in just 10 months
-Women who engaged with coaching, tracking, and digital support lost even more, over 21%
-Over 96% lost at least 5% of their body weight, and 90% lost 10% or more

PCOS affects up to 1 in 10 women and often makes weight loss incredibly challenging. These results highlight the effectiveness of Tirzepatide when paired with consistent support and guidance.

While further research is needed on biomarkers and symptom improvement, this represents a significant step forward in helping women manage PCOS, insulin resistance, and long-term metabolic health.

Semaglutide is another highly effective option for weight loss and insulin resistance — and many women with PCOS respond exceptionally well to it. Both medications work on similar pathways, but Tirzepatide combines two hormone receptors for potentially stronger results.

If you’re struggling with PCOS or weight that won’t budge, you’re not alone, and you have options.

Send us a message to see if Tirzepatide/semaglutide could be right for you.

Cite this: Tirzepatide Significantly Lowers Weight in Women With PCOS - Medscape - November 13, 2025.

’sHealth

11/10/2025

U.S. Food and Drug Administration (FDA) is initiating the removal of broad “black box” warnings from HRT (hormone replacement Therapy) products for menopause.

"As women go through menopause, the ovaries produce less estrogen and progesterone. FDA-approved HRT containing estrogen and progesterone (or estrogen alone as indicated for postmenopausal women without a uterus) can restore these declining hormones and relieve symptoms such as hot flashes, night sweats, sleep disturbances, and bone loss."

Randomized studies show that women who initiate HRT within 10 years of the onset of menopause (generally before age 60) have a reduction in all-cause mortality and fractures. Women may also reduce their risk of cardiovascular diseases by as much as 50%, Alzheimer’s disease by 35%, and bone fractures by 50 to 60%.

The FDA is NOT seeking to remove the boxed warning for endometrial cancer for systemic estrogen-alone products.

The U.S. Department of Health and Human Services (HHS) today announced historic action to restore gold-standard science to women’s health.

10/27/2025

Testosterone Therapy: Unlocking Better Health, Strength, and Vitality—No Added Heart or Cancer Risk

A comprehensive meta-analysis covering studies up to July 2025 confirms that testosterone replacement therapy improves libido, erectile function, lean mass, bone density, and insulin sensitivity—without increasing the risk for major cardiovascular events or prostate cancer when patients are appropriately monitored.

Erythrocytosis continues to be the most frequent side effect observed, highlighting the importance of regular follow-up during therapy.
www.inhousemedicine.com
(Source: Testosteron Replacement Therapy in Men Aged 50 and Above, September 2025. NIH PMC)

Call now to connect with business.

10/24/2025

Testosterone therapy in men with diabetes and hypogonadism may reduce risks of kidney injury, cardiovascular events, and mortality. The study suggests considering testosterone as a potential intervention for renal protection in this population.

Testosterone Protects Renal Health in Men With Diabetes - Medscape - October 09, 2025.

If you’re interested in Testosterone therapy come check us out.
Inhousemedicine.com/testosterone

We accept insurance. Obtain your Wegovy and Zepbound if you qualify from the pharmacy.

10/19/2025

Semaglutide: Targeting Fat While Protecting Muscle

At InHouse Medical, we focus on more than just weight loss, we focus on helping you lose fat while keeping your strength.

A recent study published in Diabetes, Obesity and Metabolism found that people using once-weekly semaglutide (2.4 mg) for 12 months lost a significant amount of body fat while preserving lean muscle mass and even improving muscle strength.

Here’s what researchers discovered:
✅ Average weight loss: 12.7% after one year
✅ Fat mass decreased by nearly 19%
✅ Muscle strength improved (handgrip up by 4 kg)
✅ Metabolism increased, supporting long-term results

These findings show that semaglutide doesn’t just change the scale, it supports a healthier body composition and stronger, more efficient metabolism.

At InHouse Medical, we use this research-based approach to help our patients achieve lasting success while maintaining their energy and strength.

Learn more or schedule your consultation today at InHouseMedicine.com

Source: MEDBRIEF “Semaglutide Targets Fat While Protecting Muscle Mass,” edited by Shrabasti Bhattacharya, October 17, 2025. Published in Diabetes, Obesity and Metabolism.